Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 12:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 1,709 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Human Immunodeficiency Virus Infection (HIV) Clear all

Conditions: SARS-CoV Infection, Covid19
Interventions: Not listed
Lead sponsor: University of Miami; Other
Eligibility: 3 Years to 25 Years
Enrollment: 64 participants
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Infection, Human Immunodeficiency Virus
Interventions: GSK1265744 30mg, Placebo, GSK1265744 5mg; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 4
States / cities: Fort Lauderdale, Florida • Orlando, Florida • Vero Beach, Florida + 1 more

Conditions: Pneumococcal Infection
Interventions: PPV23; Biological
Lead sponsor: University of Toledo Health Science Campus; Other
Eligibility: 19 Years to 65 Years
Enrollment: 124 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Toledo, Ohio

Conditions: HIV Infections
Interventions: GSK3640254, Dolutegravir, Lamivudine capsules, Lamivudine tablets; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 8
States / cities: Bakersfield, California • Palm Springs, California • Denver, Colorado + 5 more

Conditions: Human Immunodeficiency Virus
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: HIV Infections
Interventions: Hepatitis A Vaccine (Inactivated); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 21 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 47
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 34 more

Conditions: HIV
Interventions: Auranofin; Drug
Lead sponsor: Vaccine and Gene Therapy Institute, Florida; Other
Eligibility: 18 Years to 55 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2017
U.S. locations: 1
States / cities: Miami, Florida

Conditions: HIV-1-infection, Alcohol Drinking
Interventions: Alcohol, ethyl, moderate dose, Placebo; Other
Lead sponsor: Brown University; Other
Eligibility: 21 Years to 60 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: HIV Infections
Interventions: Lamivudine, Methotrexate, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2002
U.S. locations: 7
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Wichita, Kansas + 4 more

Conditions: HIV/AIDS, Insomnia
Interventions: SHUTi; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: HIV Infection
Interventions: Abacavir/Lamivudine; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 178
States / cities: Montgomery, Alabama • Glendale, Arizona • Phoenix, Arizona + 123 more

Conditions: HIV Infections
Interventions: TPV oral solution, RTV oral solution; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 9
States / cities: Los Angeles, California • Hartford, Connecticut • Chicago, Illinois + 5 more

Conditions: HIV Infection, Substance Abuse
Interventions: empowerment theory-based small group discussion, individual resilience counseling; Behavioral
Lead sponsor: Nova Southeastern University; Other
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 515 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 2
States / cities: Miami Beach, Florida • Wilton Manors, Florida

Conditions: HIV Infection
Interventions: abacavir/lamivudine/zidovudine, tenofovir; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 27
States / cities: Los Angeles, California • San Rafael, California • Fort Lauderdale, Florida + 22 more

Conditions: Infection, Human Immunodeficiency Virus
Interventions: BMS-663068, Darunavir, Cobicistat; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Hypertriglyceridemia, HIV Infection
Interventions: Lovaza, fosamprenavir/ritonavir; Dietary Supplement · Drug
Lead sponsor: Felizarta, Franco, M.D.; Individual
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Bakersfield, California

Conditions: Human Immunodeficiency Virus (HIV), Hepatitis C, Chronic
Interventions: Not listed
Lead sponsor: George Washington University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: HIV
Interventions: HXTC infusion; Biological
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: HIV Infections, HIV Seronegativity, Herpes Genitalis
Interventions: Acyclovir, Acyclovir placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 3,682 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 3
States / cities: San Francisco, California • New York, New York • Seattle, Washington

Conditions: HIV Infections
Interventions: Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Months to 18 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1995
U.S. locations: 49
States / cities: Long Beach, California • Los Angeles, California • Oakland, California + 33 more

Conditions: Hiv, HIV Infections, Sexually Transmitted Infection, Sexually Transmitted Diseases, Sexual Behavior, Risk Reduction
Interventions: Intervention LuvHub, Waitlist Control LuvHub; Behavioral
Lead sponsor: Florida International University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 778 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Miami, Florida

Conditions: HIV Infections
Interventions: Zidovudine, Didanosine; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 3 Months to 18 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1995
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: HIV Infection
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 12 Years to 24 Years
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 16
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 11 more

Conditions: HIV Infections, HCV
Interventions: Albinterferon, Ribavirin, Albuferon; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Cross Sectional CFAR HIV/COVID-19 Study

Study to Compare the Safety and Anti-HIV Effect of GSK1265744 Versus Placebo in HIV-1 Infected Adults (ITZ112929)

Immune Response to Pneumococcal Vaccination in HIV Infected Individuals

A Clinical Trial of GSK3640254 + Dolutegravir (DTG) in Human Immunodeficiency Virus-1 Infected Treatment-naive Adults

Impact of ART Adherence on HIV Persistence and Inflammation

A Study on the Rate of Opportunistic (AIDS-Related) Infections Among HIV-Positive Children Who Have Stopped Taking Their OI Preventive Medications

Oral Auranofin for Reduction of Latent Viral Reservoir in Patients With HIV Infection

Acute Neural and Immune Effects of Alcohol in People Living With HIV Infection

A Phase I Study of Methotrexate for HIV Infection

Cognitive Behavioral Therapy to Treat Insomnia in Persons With HIV Infection

A Study Comparing Safety Of Abacavir And Lamivudine Administered Once-Daily As A Single Tablet Versus The Same Drugs Administered Twice-Daily As Separate Tablets (ALOHA Study)

Pharmacokinetics and Safety Study of Tipranavir in Combination With Low Dose Ritonavir in Human Immunodeficiency Virus (HIV)-Infected Children

Risk Reduction for Urban Substance Using Men Who Have Sex With Men (MSM)

Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure

A Phase 1 Antiretroviral Drug-Drug Interaction Study in Healthy Volunteers (DDI)

Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects

The Effect of HIV Tat Protein on HCV Replication in an In-vitro Model System

Phase I Study of HIV 1 Antigen Expanded Specific T Cell Therapy

A Study of Acyclovir to Help Prevent HIV Infection in People With Genital Herpes

A Study of Dideoxyinosine (ddI) in HIV-Infected Children Who Have Not Had Success With Zidovudine or Who Cannot Take Zidovudine

Personalized Prevention for Couples: A 16-month Digital RCT

A Phase I Study to Evaluate the Safety and Toxicity of the Combination of Zidovudine and 2',3'-Dideoxyinosine (Didanosine) in Children With HIV Infection

Typology of Adherence in Adolescents: Phase II

An Open Label Non-Randomized Dose Escalating Trial to Assess Safety and Tolerability of Alb-Interferon Alfa 2b Every Two Weeks With Ribavirin Among HIV/HCV Coinfected Individuals